Merck KGaA posts higher earnings, profits across business segments

Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

Ascentage Pharma and Tanner Pharma Group initiate a global innovative named Patient Program

Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.

Funds for R&D in drug discovery and manufacturing :PIB

An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Roche launches Elecsys HCV Duo immunoassay for hepatitis C virus

Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.

Think twice even before you start thinking on smoking!

Tobacco smoke increases infant morbidity and is fatal to a baby because it damages the baby’s organs

Strand Life Sciences presents report on ‘Genomic Surveillance of SARS-CoV-2’

Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru

Merck and Orion collaborate for the development and commercialization of ODM-208

Orion to receive an upfront payment of USD 290 million

ProBioGen partners with Granite Bio for cell line development and GMP manufacturing services

Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B